Literature DB >> 34162676

Daptomycin in combination with rosuvastatin induced blood creatine phosphokinase elevation.

Mefküre Durmuş1, Ömer Faruk Bahçecioğlu2, Selim Gök1.   

Abstract

We present the case of a 73-year-old male patient who was hospitalised with infective endocarditis, and report an elevation in his blood creatine phosphokinase (CPK) after receiving daptomycin and rosuvastatin therapy concomitantly. His previous home-scheduled medications included apixaban, ivabradine, metformin, rosuvastatin 20 mg, ginkgo biloba and trimetazidine, and he continued to receive these medications at the hospital. After three sets of blood cultures were taken, empirical treatment was started with vancomycin and gentamicin. On the eighth day of treatment, daptomycin and ampicillin-sulbactam were initiated due to ampicillin-resistant Enterococcus faecalis growth in the patient's blood culture. Daptomycin and rosuvastatin were discontinued on the 23rd day of treatment because of blood CPK elevation (2416 U/L) and linezolid was started instead of daptomycin. Six days after discontinuation of daptomycin and rosuvastatin, the CPK concentrations returned to normal range. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiology; case report; clinical pharmacy; infection control; side effects of drugs

Mesh:

Substances:

Year:  2020        PMID: 34162676      PMCID: PMC8239264          DOI: 10.1136/ejhpharm-2020-002218

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  15 in total

1.  Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy.

Authors:  J Parra-Ruiz; C Dueñas-Gutiérrez; C Tomás-Jiménez; J P Linares-Palomino; J Garrido-Gomez; J Hernández-Quero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-08       Impact factor: 3.267

2.  The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.

Authors:  Alawi A Alsheikh-Ali; Marietta S Ambrose; Jeffrey T Kuvin; Richard H Karas
Journal:  Circulation       Date:  2005-05-23       Impact factor: 29.690

Review 3.  Clinical perspectives of statin-induced rhabdomyolysis.

Authors:  Kenneth A Antons; Craig D Williams; Steven K Baker; Paul S Phillips
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

Review 4.  Rosuvastatin induced rhabdomyolysis in a low risk patient: a case report and review of the literature.

Authors:  Fahmi Yousef Khan; Wael Ibrahim
Journal:  Curr Clin Pharmacol       Date:  2009-01

5.  Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States.

Authors:  P Brandon Bookstaver; Christopher M Bland; Zaina P Qureshi; Carmen M Faulkner-Fennell; Margrit A Sheldon; Celeste R Caulder; Charles Hartis
Journal:  Pharmacotherapy       Date:  2013-05-26       Impact factor: 4.705

6.  Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.

Authors:  Larry K Golightly; Gerard R Barber; Michelle A Barron; Robert L Page
Journal:  Drug Metabol Drug Interact       Date:  2013

7.  Rosuvastatin (Crestor) and rhabdomyolysis.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

8.  Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.

Authors:  D A Figueroa; E Mangini; M Amodio-Groton; B Vardianos; A Melchert; C Fana; W Wehbeh; C M Urban; S Segal-Maurer
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

Review 9.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

10.  Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.

Authors:  Ryan K Dare; Chad Tewell; Bryan Harris; Patty W Wright; Sara L Van Driest; Eric Farber-Eger; George E Nelson; Thomas R Talbot
Journal:  Clin Infect Dis       Date:  2018-10-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.